Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 17, 2016 07:30 ET | Source: Melinta Therapeutics, Inc.

Cempra to Report Fourth Quarter and Full Year 2015 Financial Results

CHAPEL HILL, N.C., Feb. 17, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics in the face of rising antibiotic...
February 05, 2016 07:00 ET | Source: Melinta Therapeutics, Inc.

The Lancet Infectious Diseases Publishes Positive Phase 3 Study Results for Cempra’s Oral Solithromycin in Community-Acquired Bacterial Pneumonia

Solithromycin met primary and secondary objectives of non-inferiority compared to moxifloxacin, a potent fluoroquinolone Cempra plans to complete a New Drug Application (NDA) submission to the FDA...
February 03, 2016 07:30 ET | Source: Melinta Therapeutics, Inc.

Cempra to Present at the Leerink Partners 5th Annual Global Healthcare Conference

CHAPEL HILL, N.C., Feb. 03, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
February 01, 2016 07:30 ET | Source: Melinta Therapeutics, Inc.

Cempra and Macrolide Pharmaceuticals Enter Synthetic Manufacturing Process Development Agreement for Solithromycin

CHAPEL HILL, N.C. and WATERTOWN, Mass., Feb. 01, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (NASDAQ:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical...
January 26, 2016 08:00 ET | Source: Melinta Therapeutics, Inc.

Cempra to Ring NASDAQ Closing Bell to Mark 10th Anniversary

CHAPEL HILL, N.C., Jan. 26, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
January 12, 2016 16:05 ET | Source: Melinta Therapeutics, Inc.

Cempra Completes Public Offering of Common Stock

CHAPEL HILL, N.C., Jan. 12, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
January 06, 2016 20:42 ET | Source: Melinta Therapeutics, Inc.

Cempra Prices Public Offering of Common Stock

CHAPEL HILL, N.C., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
January 06, 2016 07:30 ET | Source: Melinta Therapeutics, Inc.

Cempra to Present at J.P. Morgan Healthcare Conference

CHAPEL HILL, N.C., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
January 05, 2016 16:10 ET | Source: Melinta Therapeutics, Inc.

Cempra Announces Proposed Public Offering of $175 Million of Common Stock

CHAPEL HILL, N.C., Jan. 05, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
January 05, 2016 07:00 ET | Source: Melinta Therapeutics, Inc.

Cempra Doses Initial Patient in Phase 2 Clinical Trial of Solithromycin in NASH

CHAPEL HILL, N.C., Jan. 05, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right